FDA Announces Thoratec Voluntary Device Correction Letter

The U.S. Food and Drug Administration (FDA) on Sept. 14 announced that a voluntary device correction letter was sent from Thoratec Corporation concerning the HeartMate II LVAS. The letter reminds hospitals to “monitor the expiration date of the backup battery contained within the HeartMate II ‘Pocket’ System Controller”. According to Thoratec Corporation, the backup battery has a 36 month expiration date. If the expiration date passes, an advisory alarm will sound, but the HeartMate II LVAS will continue to function normally.

Read the FDA’s announcement.

Clinical Topics: Cardiac Surgery, Heart Failure and Cardiomyopathies, Cardiac Surgery and Heart Failure, Mechanical Circulatory Support

Keywords: Heart-Assist Devices, Hospitals, Monitoring, Physiologic, United States Food and Drug Administration

< Back to Listings